A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.
Inclusion Criteria
Exclusion Criteria
Ciudad Autonoma Buenos Aires, C1430EGF, Argentina
Bogota, D.C., 110131, Colombia
Praha 4 - Krc, 140 59, Czechia
Meldola, Emilia-Romagna 47014, Italy
Torrette, Tuscany 60020, Italy
Kaunas, 50009, Lithuania
Krasnoyarsk, Krasnodarskiy Kray 660133, Russia
Chelyabinsk, Moscow Oblast 454087, Russia
Edirne, 22030, Turkey (Türkiye)
Izmir, 35110, Turkey (Türkiye)
Hochiminh City, 700000, Vietnam